Introduction: H-NIV is widely used in the treatment of chronic respiratory failure (CRF). We report  patient characteristics and clinical outcome.

Method:Retrospective observational data in random sample selection of our cohort(Mar 22-June 22)

Results: 229 patients prescribed H-NIV therapy were sampled, mean (SD) age 68.3 (11.2) years; male 53%, most common indication was Obesity Hypoventilation Syndrome (OHS) ± obstructive sleep apnoea (OSA)(58%), followed by Emphysema (19%). 78% of our sample cohort were alive during data collection (Table 1). Time to death (median) in out-patient set ups (n=16) was 46 months compared to 33.5 months in setups as in-patient (n=35) immediately after post-Acute Hypercapnic Respiratory Failure (Post-AHRF) (Figure 1). Mean survival was better in patients with combined Emphysema and Sleep disordered breathing (SDB) compared to Emphysema alone. Our study shows similar outcomes in survival compared to a large European study (Thorax. 2020 Nov 1;75(11):965-73)

Conclusion: Our real-world observational data demonstrates 78% survival in H-NIV patients for all indications in our sample.